• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Authors' Reply to Reed and Colleagues' Comment on "Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review".

作者信息

Moghadamnia Marjan, Dashti-Khavidaki Simin

机构信息

Department of Pharmacotherapy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, P.O.Box: 1417614411, Tehran, Iran.

出版信息

Paediatr Drugs. 2025 Sep;27(5):667-669. doi: 10.1007/s40272-025-00704-7. Epub 2025 Jun 11.

DOI:10.1007/s40272-025-00704-7
PMID:40498299
Abstract
摘要

相似文献

1
Authors' Reply to Reed and Colleagues' Comment on "Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review".作者对里德及其同事就《mTOR抑制剂在小儿肝移植受者中的作用：一项系统评价》所做评论的回复
Paediatr Drugs. 2025 Sep;27(5):667-669. doi: 10.1007/s40272-025-00704-7. Epub 2025 Jun 11.
2
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.用于治疗肾移植受者中已存在的和新发糖尿病的降糖药物。
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD009966. doi: 10.1002/14651858.CD009966.pub2.
3
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.肾移植受者使用的HMG CoA还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD005019. doi: 10.1002/14651858.CD005019.pub4.
4
Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.抗病毒预防对实体器官移植受者EBV病毒血症及移植后淋巴细胞增生性疾病的影响：一项系统评价与荟萃分析
Virol J. 2025 Jan 15;22(1):11. doi: 10.1186/s12985-025-02623-y.
5
Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.肝移植受者钙调神经磷酸酶抑制剂最小化与继续使用钙调神经磷酸酶抑制剂治疗的比较
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD008852. doi: 10.1002/14651858.CD008852.pub2.
6
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.
7
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.mTOR 抑制剂在实体器官移植受者中是否更常出现伤口并发症或淋巴囊肿？一项随机对照试验的系统评价。
Transpl Int. 2011 Dec;24(12):1216-30. doi: 10.1111/j.1432-2277.2011.01357.x. Epub 2011 Sep 29.
8
Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.钠-葡萄糖协同转运蛋白2抑制剂在患有2型糖尿病或移植后糖尿病的实体器官移植受者中的应用：一项系统评价。
Transplant Rev (Orlando). 2023 Jan;37(1):100729. doi: 10.1016/j.trre.2022.100729. Epub 2022 Nov 4.
9
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.提高实体器官移植受者免疫抑制剂药物依从性的干预措施。
Cochrane Database Syst Rev. 2022 Sep 12;9(9):CD012854. doi: 10.1002/14651858.CD012854.pub2.
10
Subclinical cardiovascular changes in pediatric solid organ transplant recipients: A systematic review and meta-analysis.小儿实体器官移植受者的亚临床心血管变化：一项系统评价和荟萃分析。
Pediatr Transplant. 2016 Jun;20(4):530-9. doi: 10.1111/petr.12689. Epub 2016 Feb 18.

本文引用的文献

1
Sirolimus to treat chronic and steroid-resistant allograft rejection-related fibrosis in pediatric liver transplantation.西罗莫司治疗小儿肝移植中慢性和激素抵抗的移植物排斥反应相关纤维化。
J Pediatr Gastroenterol Nutr. 2024 Nov;79(5):962-968. doi: 10.1002/jpn3.12286. Epub 2024 Jul 8.
2
Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients.mTOR 抑制剂在实体器官移植受者中剂量调整的药代动力学原则。
J Clin Pharm Ther. 2022 Sep;47(9):1362-1367. doi: 10.1111/jcpt.13753. Epub 2022 Aug 7.
3
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
儿童肝移植患者中供体 CYP3A5 基因型和移植物与受者体重比对他克莫司药代动力学的早期影响。
Sci Rep. 2021 Jan 11;11(1):443. doi: 10.1038/s41598-020-79574-7.
4
Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.供体和受者 P450 基因多态性影响中国肝移植患者他克莫司的个体药物代谢动力学效应。
Int Immunopharmacol. 2018 Apr;57:18-24. doi: 10.1016/j.intimp.2018.02.005. Epub 2018 Feb 15.
5
Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.环孢素和西罗莫司在肾移植受者中的药代动力学和药物相互作用。
Fundam Clin Pharmacol. 2009 Oct;23(5):625-31. doi: 10.1111/j.1472-8206.2009.00699.x. Epub 2009 Jul 28.
6
Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.接受钙调神经磷酸酶抑制剂联合治疗的儿科肾移植受者中西罗莫司的药代动力学
Pediatr Transplant. 2006 Dec;10(8):914-9. doi: 10.1111/j.1399-3046.2006.00541.x.
7
Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.西罗莫司和他克莫司在儿科移植患者中的药代动力学
Am J Transplant. 2004 May;4(5):767-73. doi: 10.1111/j.1600-6143.2004.00411.x.
8
Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers.健康志愿者口服西罗莫司与微乳环孢素联合给药且间隔4小时时的药代动力学相互作用。
J Clin Pharmacol. 2003 Oct;43(10):1168-76. doi: 10.1177/0091270003257227.
9
Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.
J Clin Pharmacol. 2002 Jan;42(1):95-9. doi: 10.1177/0091270002042001011.